Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00048152 · ClinicalTrials.gov registry record · Phase 3
A Study to Assess Use of Zenapax (Daclizumab) and CellCept (Mycophenolate Mofetil) to Improve Kidney Function in Kidney Transplant Patients
A Phase 3 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 3
- Development phase
- 539
- Enrollment target
NCT00048152 is a Phase 3 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 539 participants.
The verdict
NCT00048152, a Phase 3 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 539 participants
- Enrollment target
Study Summary
This study will compare kidney function in kidney transplant patients following treatment with various combinations of Zenapax, CellCept, corticosteroids, and Neoral (Cyclosporine). The anticipated time on study treatment is 6-12 months, and the target sample size is 500+ individuals.
Interventions
- DRUG Corticosteroids
- DRUG Zenapax
- DRUG mycophenolate mofetil [CellCept]
- DRUG Neoral
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 539 participants |
| Start Date | 2000-12 |
| Est. Completion | 2006-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00048152
The ClinicalTrials.gov registry entry for NCT00048152 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 539 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Corticosteroids is the first listed.
NCT00048152 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00048152 about?
NCT00048152 is a clinical study titled "A Study to Assess Use of Zenapax (Daclizumab) and CellCept (Mycophenolate Mofetil) to Improve Kidney Function in Kidney Transplant Patients". This study will compare kidney function in kidney transplant patients following treatment with various combinations of Zenapax, CellCept, corticosteroids, and Neoral (Cyclosporine). The anticipated time on study treatment is 6-12 months, and the target sample size is 500+ individuals.
What is the current status of trial NCT00048152?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 539 participants. The study started on 2000-12. Estimated completion is 2006-03.
What interventions are being tested in trial NCT00048152?
The interventions under investigation include: Corticosteroids (DRUG), Zenapax (DRUG), mycophenolate mofetil [CellCept] (DRUG), Neoral (DRUG).
Who is sponsoring clinical trial NCT00048152?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.